Taken together these data suggested that in vivo treatment of IL-33 may have beneficial effects in MLD-STZ diabetes by promoting Tregs and in particular ST2+ Tregs producing IL-10 and possibly IL-5 and/or IL-13. The gene discussed is IL33; the disease is diabetes mellitus.